Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation

Abstract Some patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were ret...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryo Yamazaki, Osamu Nishiyama, Sho Saeki, Hiroyuki Sano, Takashi Iwanaga, Yuji Tohda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/efa573444f064c61afdfcc6679e85883
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:efa573444f064c61afdfcc6679e85883
record_format	dspace
spelling	oai:doaj.org-article:efa573444f064c61afdfcc6679e858832021-12-02T13:20:04ZInitial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation10.1038/s41598-021-85234-12045-2322https://doaj.org/article/efa573444f064c61afdfcc6679e858832021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85234-1https://doaj.org/toc/2045-2322Abstract Some patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were retrospectively recruited. Of 63 patients admitted for an AE-IPF and discharged alive, 9 (14.3%) developed a recurrence of AE within 1 year. The mean time to recurrence was 233 ± 103 days. Total doses (mg/month and mg/kg/month) of corticosteroids administered over day 1 to 30 after the AE were significantly higher in patients without recurrences of AE-IPF (5185 ± 2414 mg/month, 93.5 ± 44.0 mg/kg/month) than the doses in patients with recurrences (3133 ± 1990 mg/month, 57.2 ± 37.7 mg/kg/month) (p = 0.02 and p = 0.03, respectively). However, no differences were observed between the total doses of corticosteroids administered over days 31 to 60, 61 to 90, 91 to 120, and 151 to 180 after the AE. Furthermore, differences between the administration rates of immunosuppressive and antifibrotic treatments administered to the 2 patient groups were not significant. An increased total dose of corticosteroid administered over day 1 to 30 after an AE-IPF was associated with a decreased risk of subsequent recurrence of AE-IPF within 1 year after the first AE.Ryo YamazakiOsamu NishiyamaSho SaekiHiroyuki SanoTakashi IwanagaYuji TohdaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ryo Yamazaki Osamu Nishiyama Sho Saeki Hiroyuki Sano Takashi Iwanaga Yuji Tohda Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
description	Abstract Some patients with idiopathic pulmonary fibrosis (IPF) undergo recurrent acute exacerbations (AEs). This study aimed to elucidate the risk factors for recurrent AEs of IPF (AE-IPF). Consecutive patients with IPF admitted for their first AE-IPF between January 2008 and December 2018 were retrospectively recruited. Of 63 patients admitted for an AE-IPF and discharged alive, 9 (14.3%) developed a recurrence of AE within 1 year. The mean time to recurrence was 233 ± 103 days. Total doses (mg/month and mg/kg/month) of corticosteroids administered over day 1 to 30 after the AE were significantly higher in patients without recurrences of AE-IPF (5185 ± 2414 mg/month, 93.5 ± 44.0 mg/kg/month) than the doses in patients with recurrences (3133 ± 1990 mg/month, 57.2 ± 37.7 mg/kg/month) (p = 0.02 and p = 0.03, respectively). However, no differences were observed between the total doses of corticosteroids administered over days 31 to 60, 61 to 90, 91 to 120, and 151 to 180 after the AE. Furthermore, differences between the administration rates of immunosuppressive and antifibrotic treatments administered to the 2 patient groups were not significant. An increased total dose of corticosteroid administered over day 1 to 30 after an AE-IPF was associated with a decreased risk of subsequent recurrence of AE-IPF within 1 year after the first AE.
format	article
author	Ryo Yamazaki Osamu Nishiyama Sho Saeki Hiroyuki Sano Takashi Iwanaga Yuji Tohda
author_facet	Ryo Yamazaki Osamu Nishiyama Sho Saeki Hiroyuki Sano Takashi Iwanaga Yuji Tohda
author_sort	Ryo Yamazaki
title	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
title_short	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
title_full	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
title_fullStr	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
title_full_unstemmed	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation
title_sort	initial therapeutic dose of corticosteroid for an acute exacerbation of ipf is associated with subsequent early recurrence of another exacerbation
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/efa573444f064c61afdfcc6679e85883
work_keys_str_mv	AT ryoyamazaki initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation AT osamunishiyama initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation AT shosaeki initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation AT hiroyukisano initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation AT takashiiwanaga initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation AT yujitohda initialtherapeuticdoseofcorticosteroidforanacuteexacerbationofipfisassociatedwithsubsequentearlyrecurrenceofanotherexacerbation
_version_	1718393247735218176

Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation

Ejemplares similares